Ocrelizumab, an experimental new treatment option for MS, has had promising results in recent Phase III clinical trials for both primary progressive MS and relapsing-remitting MS. To find out more, click on the link below:
Ocrelizumab shows the way forward for research into treatments for progressive forms of MS
Article courtesy of MS Research Australia www.msra.org.au